FDA sends interim peptide compounding policy to White House budget office for review
The Food and Drug Administration has sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Information and Regulatory Affairs, which received it on October 14, 2026 and lists it as pending review. The policy text has not been published, so nothing changes for patients or pharmacies yet - but the filing is the clearest signal yet that FDA is preparing a defined position on compounded peptides.
The Office of Information and Regulatory Affairs (OIRA), part of the White House Office of Management and Budget, lists the submission under regulation identifier number 0910-ZD94, titled "Interim Access Policy for Compounding Using Certain Peptides." The record shows it was received on October 14, 2026, is at the Notice stage, carries no legal deadline, and is not classified as economically significant. OIRA review under Executive Order 12866 is a standard step before a federal agency releases significant policy; the listing does not say when, or whether, the policy will be published.
The title suggests FDA is weighing a formal access pathway for compounding with certain peptides through licensed pharmacies, a channel distinct from the unregulated "research use" websites where many of these substances are currently sold. No list of covered peptides or conditions has been made public, and any description of what the policy contains is speculation until the text appears.
The submission lands amid an active FDA posture on peptides. According to reporting by longevitydocs, FDA's page on bulk drug substances that may present significant safety risks (the Category 2 list) now shows 16 peptides - including BPC-157, TB-500, MOTS-c, thymosin alpha-1, injectable GHK-Cu, epitalon and semax - marked as previously listed and withdrawn by their nominators, while ipamorelin, GHRP-2, GHRP-6, kisspeptin-10 and ibutamoren remain on the active list. The agency's Pharmacy Compounding Advisory Committee met on July 23 and 24 to consider seven peptides for the 503A bulks list; FDA staff proposed against listing BPC-157, KPV, TB-500 and MOTS-c, citing poor characterization, immunogenicity concerns and limited human data, and the committee's votes have not been posted.
FDA also maintains that retatrutide, Eli Lilly's investigational triple agonist, cannot be used in compounding under federal law, and issued warning letters to online sellers in August calling it an unapproved new drug. Lilly has separately sued peptide sellers and pharmacies and says it has reported more than 14,000 online listings.
For patients, the practical position is unchanged: compounded peptides sourced outside licensed 503A pharmacies lack the quality controls of approved medicines or properly compounded preparations, and no new legal pathway exists until FDA publishes the policy and it takes effect. Peptide Health Directory will review the policy text when it is released.